Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We are delighted to announce that Professor KJ Patel has been appointed as the new Director of the MRC Weatherall Institute of Molecular Medicine and the MRC Molecular Haematology Unit at the University of Oxford.

Professor KJ Patel

Professor KJ Patel FRS FMedSci will start full-time as Director of the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) and the MRC Molecular Haematology Unit (MRC MHU) from 1st June 2020. Between 1st April to 31st May, Professor Patel will be managing these two roles on a part-time basis, whilst transitioning his research programme from the MRC Laboratory of Molecular Biology in Cambridge (MRC LMB), where he is currently based.

Professor Hugh Watkins, Head of the Radcliffe Department of Medicine, said “I am delighted to welcome KJ to the department and am excited about his vision for the MRC MHU and the MRC WIMM. KJ is a scientist of the highest distinction whose own work epitomises how fundamental molecular insights drive important medical advances.”

Read more on the MRC WIMM website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.